Loading...

Collagen Solutions

AIM:COS
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
COS
AIM
£17M
Market Cap
  1. Home
  2. GB
  3. Pharmaceuticals & Biotech
Company description

Collagen Solutions plc sources, develops, manufactures, and supplies medical grade collagen components and biomaterials for use in research, regenerative medicines, medical devices, and in-vitro diagnostics in Europe, the Middle East, Africa, North America, and Asia. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • Collagen Solutions has significant price volatility in the past 3 months.
COS Share Price and Events
7 Day Returns
1.3%
AIM:COS
-0.6%
GB Biotechs
-0.6%
GB Market
1 Year Returns
48.1%
AIM:COS
24.2%
GB Biotechs
-2.2%
GB Market
COS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Collagen Solutions (COS) 1.3% -16.3% 6.9% 48.1% -53.3% -54.7%
GB Biotechs -0.6% 2.5% 3.6% 24.2% 11.7% 53.2%
GB Market -0.6% 1.4% 0.4% -2.2% 11.5% 6.7%
1 Year Return vs Industry and Market
  • COS outperformed the Biotechs industry which returned 24.2% over the past year.
  • COS outperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -2.2% over the past year.
Price Volatility
COS
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Collagen Solutions undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Collagen Solutions. This is due to cash flow or dividend data being unavailable. The share price is £0.0385.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Collagen Solutions's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Collagen Solutions's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
AIM:COS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in GBP £-0.01
AIM:COS Share Price ** AIM (2019-07-15) in GBP £0.04
United Kingdom of Great Britain and Northern Ireland Biotechs Industry PE Ratio Median Figure of 5 Publicly-Listed Biotechs Companies 34.85x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 790 Publicly-Listed Companies 16.48x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Collagen Solutions.

AIM:COS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= AIM:COS Share Price ÷ EPS (both in GBP)

= 0.04 ÷ -0.01

-7.5x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Collagen Solutions is loss making, we can't compare its value to the GB Biotechs industry average.
  • Collagen Solutions is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does Collagen Solutions's expected growth come at a high price?
Raw Data
AIM:COS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -7.5x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
41.1%per year
United Kingdom of Great Britain and Northern Ireland Biotechs Industry PEG Ratio Median Figure of 5 Publicly-Listed Biotechs Companies 1.52x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 572 Publicly-Listed Companies 1.45x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Collagen Solutions, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Collagen Solutions's assets?
Raw Data
AIM:COS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in GBP £0.05
AIM:COS Share Price * AIM (2019-07-15) in GBP £0.04
United Kingdom of Great Britain and Northern Ireland Biotechs Industry PB Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 2.51x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,377 Publicly-Listed Companies 1.5x
AIM:COS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= AIM:COS Share Price ÷ Book Value per Share (both in GBP)

= 0.04 ÷ 0.05

0.81x

* Primary Listing of Collagen Solutions.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Collagen Solutions is good value based on assets compared to the GB Biotechs industry average.
X
Value checks
We assess Collagen Solutions's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Collagen Solutions has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Collagen Solutions expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Collagen Solutions expected to grow at an attractive rate?
  • Unable to compare Collagen Solutions's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Collagen Solutions's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.
  • Collagen Solutions's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
AIM:COS Future Growth Rates Data Sources
Data Point Source Value (per year)
AIM:COS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 41.1%
AIM:COS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 12.4%
United Kingdom of Great Britain and Northern Ireland Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 12.4%
United Kingdom of Great Britain and Northern Ireland Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 3.9%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 10.9%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
AIM:COS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in GBP Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
AIM:COS Future Estimates Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-03-31 5 0 -1 1
2020-03-31 5 -2 -1 1
AIM:COS Past Financials Data
Date (Data in GBP Millions) Revenue Cash Flow Net Income *
2019-03-31 4 -1 -2
2018-12-31 4 -2 -2
2018-09-30 4 -2 -2
2018-06-30 4 -2 -2
2018-03-31 4 -3 -3
2017-12-31 4 -3 -2
2017-09-30 4 -3 -2
2017-06-30 4 -2 -2
2017-03-31 4 -1 -2
2016-12-31 4 -1 -2
2016-09-30 4 -1 -2
2016-06-30 3 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Collagen Solutions is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Collagen Solutions's revenue is expected to grow by 12.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
AIM:COS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Collagen Solutions Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:COS Future Estimates Data
Date (Data in GBP Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-03-31 0.00 0.00 0.00 1.00
2020-03-31 0.00 0.00 0.00 1.00
AIM:COS Past Financials Data
Date (Data in GBP Millions) EPS *
2019-03-31 -0.01
2018-12-31 -0.01
2018-09-30 -0.01
2018-06-30 -0.01
2018-03-31 -0.01
2017-12-31 -0.01
2017-09-30 -0.01
2017-06-30 -0.01
2017-03-31 -0.01
2016-12-31 -0.01
2016-09-30 -0.01
2016-06-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Collagen Solutions will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Collagen Solutions's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Collagen Solutions has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Collagen Solutions performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Collagen Solutions's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Collagen Solutions does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Collagen Solutions's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Collagen Solutions's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Collagen Solutions's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Collagen Solutions Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

AIM:COS Past Revenue, Cash Flow and Net Income Data
Date (Data in GBP Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 4.15 -1.67 4.40
2018-12-31 3.94 -1.97 4.27
2018-09-30 3.73 -2.27 4.15
2018-06-30 3.62 -2.42 4.27
2018-03-31 3.50 -2.57 4.38
2017-12-31 3.67 -2.30 4.71
2017-09-30 3.84 -2.03 5.04
2017-06-30 3.89 -1.87 4.70
2017-03-31 3.95 -1.71 4.37
2016-12-31 3.73 -1.63 3.90
2016-09-30 3.52 -1.56 3.44
2016-06-30 3.32 -1.27 3.14
2016-03-31 3.13 -0.98 2.84
2015-12-31 2.70 -1.00 2.45
2015-09-30 2.27 -1.01 2.06
2015-06-30 1.62 -1.07 1.79
2015-03-31 0.97 -1.12 1.51
2014-09-30 0.24 -2.42 2.18
2014-06-30 0.17 -2.17 1.89
2014-03-31 0.10 -1.92 1.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Collagen Solutions has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Collagen Solutions has efficiently used its assets last year compared to the GB Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Collagen Solutions improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Collagen Solutions's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Collagen Solutions has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Collagen Solutions's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Collagen Solutions's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Collagen Solutions is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Collagen Solutions's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Collagen Solutions's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 1.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Collagen Solutions Company Filings, last reported 3 months ago.

AIM:COS Past Debt and Equity Data
Date (Data in GBP Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 15.43 2.51 1.68
2018-12-31 15.43 2.51 1.68
2018-09-30 15.98 2.48 2.56
2018-06-30 15.98 2.48 2.56
2018-03-31 16.88 2.92 5.02
2017-12-31 16.88 2.92 5.02
2017-09-30 18.42 2.91 6.74
2017-06-30 18.42 2.91 6.74
2017-03-31 20.29 1.91 8.98
2016-12-31 20.29 1.91 8.98
2016-09-30 14.41 0.09 1.66
2016-06-30 14.41 0.09 1.66
2016-03-31 13.90 0.08 2.49
2015-12-31 13.90 0.08 2.49
2015-09-30 12.25 0.08 3.10
2015-06-30 12.25 0.08 3.10
2015-03-31 12.85 0.11 3.39
2014-09-30 5.77 0.00 0.93
2014-06-30 5.77 0.00 0.93
2014-03-31 6.26 0.05 1.49
  • Collagen Solutions's level of debt (16.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0.8% vs 16.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Collagen Solutions has less than a year of cash runway based on current free cash flow.
  • Collagen Solutions has less than a year of cash runway if free cash flow continues to grow at historical rates of 31% each year.
X
Financial health checks
We assess Collagen Solutions's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Collagen Solutions has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Collagen Solutions's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Collagen Solutions dividends.
If you bought £2,000 of Collagen Solutions shares you are expected to receive £0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Collagen Solutions's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Collagen Solutions's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
AIM:COS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 706 Stocks 4.2%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

AIM:COS Future Dividends Estimate Data
Date (Data in £) Dividend per Share (annual) Avg. No. Analysts
2021-03-31
2020-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Collagen Solutions has not reported any payouts.
  • Unable to verify if Collagen Solutions's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Collagen Solutions's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Collagen Solutions has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Collagen Solutions's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Collagen Solutions afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Collagen Solutions has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Collagen Solutions's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jamal Rushdy
COMPENSATION £232,806
AGE 47
TENURE AS CEO 3.2 years
CEO Bio

Mr. Jamal D. Rushdy has been the Chief Executive Officer and Director of Collagen Solutions PLC since May 3, 2016. Mr. Rushdy served as Chief Business Officer of Collagen Solutions PLC since November 18, 2015. Mr. Rushdy served as Vice President of Global Integration at Tornier, Inc. Mr. Rushdy served as a Vice President of Global Sports Medicine, Biologics and Business Development group at Tornier N.V. since October 2010, where he led multiple acquisitions and corporate partnerships, including several focused on biologic technologies. Mr. Rushdy has over 20 years' experience in the medical device arena, specifically within two mid-size high growth public companies and three successful start-ups. He has a unique track record of building businesses with successful exits and transforming organisations through integration and performance improvement, adding value through business development and functional leadership. He is a Co-founder of Futura Biomedical and served as its General Manager. He served as a Vice President of Global Business and Corporate Development at Tornier Inc. and Tornier N.V from June 2007 to October 2010. He joined Tornier in February 2007 and served as its Vice President of US Sales Operations. He served as a Vice President of Operations & Business Development at Nexa Orthopedics, Inc. from March 17, 2006 to May 2007, where he led his division through a high-growth period driven by a significant expansion in the sales force and rapid product introductions leading to the successful acquisition of Nexa by Tornier. He served as a Director of Business Development and Marketing for DJ Orthopedics, LLC, where he also served in various leadership roles in finance and operations from June 2001 to January 2006. Mr. Rushdy holds an MBA from the University of California Graduate School of Management in Marketing and Finance and a Bachelor of Science in Mechanical Engineering from the University of California, San Diego.

CEO Compensation
  • Jamal's compensation has increased whilst company is loss making.
  • Jamal's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the Collagen Solutions management team in years:

2.8
Average Tenure
53
Average Age
  • The tenure for the Collagen Solutions management team is about average.
Management Team

Jamal Rushdy

TITLE
CEO & Director
COMPENSATION
£233K
AGE
47
TENURE
3.2 yrs

Hilary Spence

TITLE
CFO & Director
COMPENSATION
£29K
TENURE
1.5 yrs

Gill Black

TITLE
Company Secretary & VP of Global Finance
COMPENSATION
£72K
AGE
56
TENURE
5.3 yrs

Stewart White

TITLE
Consultant & Member of Scientific Advisory Board
COMPENSATION
£58K
AGE
48
TENURE
2.1 yrs

Tom Hyland

TITLE
COO, Director & Member of Scientific Advisory Board
AGE
53
TENURE
4.3 yrs

John Higgins

TITLE
Chief Technology Officer
TENURE
4 yrs

Lisa Baderoon

TITLE
Head of Investor Relations

Brad Selman

TITLE
Vice President of Global Sales & Marketing
TENURE
2.4 yrs

Diane Mitchell

TITLE
Chief Commercial Officer

Lou Ruggiero

TITLE
Chief Business Officer & Director
AGE
59
TENURE
1.3 yrs
Board of Directors Tenure

Average tenure and age of the Collagen Solutions board of directors in years:

1.5
Average Tenure
59
Average Age
  • The average tenure for the Collagen Solutions board of directors is less than 3 years, this suggests a new board.
Board of Directors

Chris Brinsmead

TITLE
Chairman
COMPENSATION
£2K
AGE
60

Jamal Rushdy

TITLE
CEO & Director
COMPENSATION
£233K
AGE
47
TENURE
3.2 yrs

Hilary Spence

TITLE
CFO & Director
COMPENSATION
£29K
TENURE
1.5 yrs

Stewart White

TITLE
Consultant & Member of Scientific Advisory Board
COMPENSATION
£58K
AGE
48
TENURE
2.1 yrs

Tom Hyland

TITLE
COO, Director & Member of Scientific Advisory Board
AGE
53
TENURE
0.8 yrs

Lou Ruggiero

TITLE
Chief Business Officer & Director
AGE
59
TENURE
0.8 yrs

Geoff Bennett

TITLE
Non-Executive Director
COMPENSATION
£10K
AGE
59

Malcolm Gillies

TITLE
Non-Executive Director
COMPENSATION
£10K
AGE
68
TENURE
6.3 yrs

Wade Rosen

TITLE
Non-Executive Director
TENURE
0.1 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Collagen Solutions individual insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
06. Jun 19 Buy Hilary Spence Individual 06. Jun 19 06. Jun 19 300,000 £0.05 £15,000
06. Jun 19 Buy Tom Hyland Individual 06. Jun 19 06. Jun 19 200,000 £0.05 £10,000
06. Jun 19 Buy Gillian Black Individual 06. Jun 19 06. Jun 19 150,000 £0.05 £7,500
06. Jun 19 Buy Malcolm Gillies Individual 06. Jun 19 06. Jun 19 847,000 £0.05 £42,350
03. Sep 18 Buy Tom Hyland Individual 03. Sep 18 03. Sep 18 115,988 £0.04 £4,999
24. Aug 18 Buy Hilary Spence Individual 23. Aug 18 23. Aug 18 220,000 £0.05 £9,900
X
Management checks
We assess Collagen Solutions's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Collagen Solutions has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Our Take On Collagen Solutions plc's (LON:COS) CEO Salary

Jamal Rushdy became the CEO of Collagen Solutions plc (LON:COS) in 2016. … First, this article will compare CEO compensation with compensation at similar sized companies. … Check out our latest analysis for Collagen Solutions How Does Jamal Rushdy's Compensation Compare With Similar Sized Companies?

Simply Wall St -

Does Collagen Solutions plc's (LON:COS) CEO Salary Compare Well With Others?

How Does Jamal Rushdy's Compensation Compare With Similar Sized Companies. … Our data indicates that Collagen Solutions plc is worth UK£14m, and total annual CEO compensation is UK£233k. … We examined a group of similar sized companies, with market capitalizations of below UK£152m

Simply Wall St -

Have Insiders Been Buying Collagen Solutions plc (LON:COS) Shares?

So shareholders might well want to know whether insiders have been buying or selling shares in Collagen Solutions plc (LON:COS). … As Peter Lynch said, 'insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.'. … The Last 12 Months Of Insider Transactions At Collagen Solutions.

Simply Wall St -

Should You Worry About Collagen Solutions plc's (LON:COS) CEO Salary Level?

First, this article will compare CEO compensation with compensation at similar sized companies. … How Does Jamal Rushdy's Compensation Compare With Similar Sized Companies. … Our data indicates that Collagen Solutions plc is worth UK£10m, and total annual CEO compensation is UK£233k.

Simply Wall St -

Are Insiders Too Confident In Collagen Solutions plc (LON:COS)?

Collagen Solutions plc develops, manufactures, and supplies medical grade collagen components and biomaterials for use in regenerative medicines, medical devices, and in-vitro diagnostics in Europe, the Middle East, Africa, North America, and Asia. … some insider buying over the past three months, with insiders investing in. … Generally, insiders buying more shares in their own firm sends a bullish signal

Simply Wall St -

Should Collagen Solutions plc's (LON:COS) Recent Earnings Decline Worry You?

Understanding Collagen Solutions plc's (LON:COS) performance as a company requires examining more than earnings from one point in time. … Today I will take you through a basic sense check to gain perspective on how Collagen Solutions is doing by evaluating its latest earnings with its longer term trend as well as its industry peers' performance over the same period. … See our latest analysis for Collagen Solutions?

Simply Wall St -

Collagen Solutions plc’s (LON:COS) Insiders Ramped Up Holdings - Should You?

AIM:COS Insider_trading May 18th 18 More shares have been bought than sold by Collagen Solutions insiders in the past three months. … Delving deeper into the line items,Collagen Solutions is expected to experience a healthy double-digit top-line growth next year, which appears to flow through to an earnings growth of 17.38%. … Next Steps: Collagen Solutions’s net buying tells us the stock is in favour with some insiders, which is fairly consistent with earnings growth expectations, as well as the significant share price volatility over the same period of trade.

Simply Wall St -

Was Collagen Solutions plc's (LON:COS) Earnings Decline Part Of A Broader Industry Downturn?

Below, I will examine Collagen Solutions plc's (AIM:COS) track record on a high level, to give you some insight into how the company has been performing against its long term trend and its industry peers. … Check out our latest analysis for Collagen Solutions Was COS's recent earnings decline worse than the long-term trend and the industry? … AIM:COS Income Statement Apr 6th 18 We can further examine Collagen Solutions's loss by looking at what the industry has been experiencing over the past few years.

Simply Wall St -

Collagen Solutions plc (LON:COS): Is Healthcare An Attractive Sector Play?

Check out our latest analysis for Collagen Solutions What’s the catalyst for Collagen Solutions's sector growth? … Collagen Solutions lags the pack with its lower growth rate of 14.42% over the past year, which indicates the company will be growing at a slower pace than its biotech peers. … If Collagen Solutions has been on your watchlist for a while, now may be the time to enter into the stock, if you like its growth prospects and are not highly concentrated in the biotech industry.

Simply Wall St -

January Top Growth Stocks

Driven by the exceptional 94.94% sales growth over the next few years, COS is expected to deliver an excellent earnings growth of 68.86%. … ARBB’s forecasted bottom line growth is an exceptional 50.88%, driven by the underlying 70.59% sales growth over the next few years. … MPAY’s projected future profit growth is an exceptional triple-digit, with an underlying 70.38% growth from its revenues expected over the upcoming years.

Simply Wall St -

Company Info

Description

Collagen Solutions plc sources, develops, manufactures, and supplies medical grade collagen components and biomaterials for use in research, regenerative medicines, medical devices, and in-vitro diagnostics in Europe, the Middle East, Africa, North America, and Asia. It offers collagen soluble collagen, collagen powders, fibrillars, collagen gels, freeze dried collagen, and other products for use in orthopaedic, sports medicine, dental, wound care, cardiovascular, general, plastic, and reconstructive surgeries, as well as 3D cell culture research; Bovine Pericardium is used in bio-prosthetic heart valves, dural closures, bone and dental membranes, and surgical buttressing applications; and BSE-free bovine biomaterials. The company also provides product development and contract manufacturing services, including technology transfer and regulatory support services for collagen-based products. It serves pharmaceutical and medical device companies. Collagen Solutions plc was incorporated in 2013 and is based in London, the United Kingdom.

Details
Name: Collagen Solutions plc
COS
Exchange: AIM
Founded: 2013
£17,081,794
443,682,981
Website: http://www.collagensolutions.com
Address: Collagen Solutions plc
Condor House,
10 St. Paul’s Churchyard,
London,
Greater London, EC4M 8AL,
United Kingdom
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
AIM COS Ordinary Shares London Stock Exchange AIM Market GB GBP 05. Apr 2013
Number of employees
Current staff
Staff numbers
48
Collagen Solutions employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/07/15 22:17
End of day share price update: 2019/07/15 00:00
Last estimates confirmation: 2019/07/09
Last earnings filing: 2019/07/09
Last earnings reported: 2019/03/31
Last annual earnings reported: 2019/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.